Most of Elite’s rev is with Adderall. That is tied up until end of March with Lannett. He cannot simply exit this contract. His job will be to execute the bridge to their sales/distribution strategy as seamless as possible. He has very limited products to work with outside Adderall. Once the R&D pipeline shifts more to approvals, then he has more to work with.
News 
Market Data 
Discover 
